Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with Gemcitabine and Radiotherapy for Pancreatic Cancer
NCT00557492Phase 2Completed
- Start
- Dec 2006
- Primary completion
- Mar 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in pancreatic adenocarcinoma (PDAC). Primary endpoints: Rate of Margin Negative Surgical Resection up to 48 months and Rate of Pathologic Complete Response up to 48 months. Started Dec 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00557492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00557492.